Clinical trial • Phase I • Immunology
Clinical trial in Eosinophilic esophagitis | Celiac disease
Phase I trial for Eosinophilic esophagitis | Celiac disease. 118 participants.
Overview
- Trial Therapeutic Area
- Immunology
- Trial Disease
- Eosinophilic esophagitis | Celiac disease
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 26-05-2025
- First CTIS Authorization Date
- 24-07-2025
Trial design
Phase I trial across 7 sites in Netherlands, Finland, Germany.
- Target Sample Size
- 118
Eligibility
Recruits 118 Vulnerable population selected; no details on consent or assent provided..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent provided.
Recruitment
- Planned Sample Size
- 118
- Recruitment Window Months
- 16
Geography
- Total Number Of Sites
- 7
- Total Number Of Participants
- 25
Netherlands
- Earliest CTIS Part Ii Submission Date
- 04-07-2025
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 315
- Number Of Sites
- 3
- Number Of Participants
- 12
Sites
- Site Name
- Amsterdam UMC Stichting
- Department Name
- Dept. of Gastroenterology
- Contact Person Name
- Gerd Bouma
- Contact Person Email
- g.bouma@amsterdamumc.nl
- Site Name
- CTC Netherlands B.V.
- Contact Person Name
- Khalid Abd-Elaziz
- Contact Person Email
- khalid.abdelaziz@ctc-netherlands.com
- Site Name
- Albert Schweitzer Ziekenhuis
- Department Name
- Maag-, Darm- en Leverziekten
- Contact Person Name
- Franciscus (Frank) Wolfhagen
- Contact Person Email
- f.wolfhagen@asz.nl
Finland
- Earliest CTIS Part Ii Submission Date
- 03-12-2025
- Latest Decision Or Authorization Date
- 15-05-2026
- Processing Time Days
- 163
- Number Of Sites
- 1
- Number Of Participants
- 3
Sites
- Site Name
- Pirkanmaan hyvinvointialue
- Department Name
- Tutkimusvastaanotto, Biokatu 10, FM 3, 2. krs.
- Contact Person Name
- Juha Taavela
- Contact Person Email
- juha.taavela@tuni.fi
Germany
- Earliest CTIS Part Ii Submission Date
- 21-11-2025
- Latest Decision Or Authorization Date
- 13-01-2026
- Processing Time Days
- 53
- Number Of Sites
- 3
- Number Of Participants
- 10
Sites
- Site Name
- University Medical Center Hamburg-Eppendorf
- Contact Person Name
- Sina Hübener
- Contact Person Email
- s.huebener@uke.de
- Site Name
- Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR
- Contact Person Name
- Detlef Schuppan
- Contact Person Email
- detlef.schuppan@unimedizin-mainz.de
- Site Name
- Universitaetsklinikum Erlangen AöR
- Contact Person Name
- Yurdagül Zopf
- Contact Person Email
- yurdaguel.zopf@uk-erlangen.de
Sponsor
Primary sponsor
- Full Name
- Anaptysbio Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Related trials
Other published trials that may interest you.
- BELIMUMAB for Antibody-mediated rejection (kidney transplant)|High HLA sensitization (transplant candidates)
- Belimumab for Systemic lupus erythematosus
- INEBILIZUMAB for Myasthenia gravis
- PREDNISONE for Granulomatosis with polyangiitis (Wegener's) | Microscopic polyangiitis | ANCA-associated vasculitis
- BIRCH POLLEN ALLERGOID GLUTARALDEHYDE MODIFIED for Allergic rhinitis due to birch pollen | Allergic rhinoconjunctivitis